

Neuralstem, Inc.  
Form 8-K  
April 13, 2017

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): April 13, 2017 (April 10, 2017)**

**Neuralstem, Inc.**

**(Exact name of registrant as specified in Charter)**

**Delaware**

**(State or other jurisdiction of  
incorporation or organization)**

**001-33672**

**(Commission File No.)**

**52-2007292**

**(IRS Employee Identification No.)**

**20271 Goldenrod Lane, 2<sup>nd</sup> Floor, Germantown, Maryland 20876**

**(Address of Principal Executive Offices)**

**(301) 366-4960**

**(Issuer Telephone number)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01**

**Other Events.**

On April 10, 2017, the compensation committee (“Committee”) of Neuralstem, Inc. (the “Company”) recommended and the board of directors (“Board”) approved the reinstatement of non-employee Board compensation for the period between July 1, 2016 and July 1, 2017. Upon reviewing the Company’s cash position, resulting primarily from its receipt of a \$20,000,000 strategic investment from Tianjin Pharmaceutical Group International Holdings Co., Ltd., the Board and Committee determined that the previously deferred annual compensation of \$100,000 per non-employee member of the Board would be reinstated and paid, at the election of each director (i) in cash, (ii) in conditional stock option grants, subject to the applicable NASDAQ rules or (iii) a combination thereof.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 13, 2017 Neuralstem, Inc.

/s/ Richard Daly  
By: Richard Daly  
Chief Executive Officer